AstraZeneca's Three-in-One COPD Inhaler Succeeds in Phase III Trial Post author:Sam Post published:January 25, 2018 Post category:BioPharma Astra has Glaxo and its COPD treatment Trelegy Ellipta squarely in its sights. Source: BioSpace You Might Also Like 9 Reasons to Buy Pfizer in 2018 and 1 Big One Not To December 21, 2017 Seattle Genetics Commences Dosing in Early-Stage Multiple Myeloma Trial March 6, 2018 The Rise and Fall of Cambridge Biotech Startup Gen9 January 24, 2017
